Subscribe To
SDGR / Schrödinger, Inc. (SDGR) Q4 2022 Earnings Call Transcript
SDGR News
By Seeking Alpha
November 1, 2023
Schrödinger, Inc. (SDGR) Q3 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice more_horizontal
By Seeking Alpha
September 29, 2023
Schrodinger: Leading The AI Healthcare Revolution
Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship more_horizontal
By Seeking Alpha
September 2, 2023
Schrodinger: More Than An AI Bubble Stock
Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively va more_horizontal
By The Motley Fool
August 3, 2023
Why Shares of Schrödinger Are Falling Thursday
Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery. more_horizontal
By Zacks Investment Research
August 2, 2023
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to lo more_horizontal
By InvestorPlace
July 11, 2023
Why These 3 Stocks Are the Best Ways to Play AI Right Now
Goldman Sachs recently asserted “that AI adoption could boost productivity growth by 1.5 percentage points per year over a 10-year period.” Th more_horizontal
By Zacks Investment Research
June 14, 2023
Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?
Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal
By InvestorPlace
May 26, 2023
3 Pharma Stocks That Will Boom Thanks to AI
A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms. more_horizontal